Myeloproliferative neoplasm (MPN) is a category in the World Health Organization
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …

Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …

HSCT remains a highly relevant treatment option for myelofibrosis in the era of JAK
inhibitors. Recent advances may contribute to a refined definition of HSCT eligibility and …

Hematopoietic cell transplantation (HCT) is the only curative therapeutic modality for
myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of …

The discovery of JAK2617F mutation paved the way for the development of small molecule
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …

Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative
therapeutic modality for patients with primary or secondary myelofibrosis (MF). However …

Myelofibrosis is one of the classical Philadelphia chromosome–negative myeloproliferative
neoplasms characterized by progressive marrow failure and chronic inflammation …

Primary myelofibrosis (PMF) is a chronic myeloid malignancy characterized by stem cell-
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …

Primary or post-ET/PV myelofibrosis is one of the Philadelphia-negative myeloproliferative
neoplasms with worst survival. Allogeneic stem cell transplantation (ASCT) can cure a …

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation,
marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic …